Short-term efficacy and safety of personalized antiplatelet therapy for patients with acute ischaemic stroke or transient ischaemic attack: A randomized clinical trial

Mengqi Han; Weijie Jia; Yifan Wu; Jie Kuang; Jianglong Tu; Shujuan Yin; Jibiao Chen; Xiaolin Zhang; Jingyi Li; Yongsen Chen; Bin Wu; Yingping Yi

doi:10.1111/bcp.15775

Short-term efficacy and safety of personalized antiplatelet therapy for patients with acute ischaemic stroke or transient ischaemic attack: A randomized clinical trial

Br J Clin Pharmacol. 2023 Sep;89(9):2813-2824. doi: 10.1111/bcp.15775. Epub 2023 May 24.

Authors

Mengqi Han^{1

2}, Weijie Jia^{1

2}, Yifan Wu^{1

2}, Jie Kuang², Jianglong Tu³, Shujuan Yin², Jibiao Chen², Xiaolin Zhang², Jingyi Li^{1

2}, Yongsen Chen^{1

2}, Bin Wu^{1

2}, Yingping Yi¹

Affiliations

¹ Department of Medical Big Data Center, The Second Affiliated Hospital of Nanchang University, Nanchang, P.R. China.
² Jiangxi Provincial Key Laboratory of Preventive Medicine, School of Public Health, Nanchang University, Nanchang, P.R. China.
³ Department of Neurology, The Second Affiliated Hospital of Nanchang University, Nanchang, P.R. China.

PMID: 37159861
DOI: 10.1111/bcp.15775

Abstract

Aims: The aim of this study was to determine whether the testing strategy for clopidogrel and/or aspirin resistance using CYP2C19 genotyping or urinary 11-dhTxB2 testing has an impact on clinical outcomes.

Methods: A multicentre, randomized, controlled trial was conducted at 14 centres in China from 2019 to 2021. For the intervention group, a specific antiplatelet strategy was assigned based on the CYP2C19 genotype and 11-dhTxB2, a urinary metabolite of aspirin, and the control group received nonguided (ie, standard of care) treatment. 11-dhTXB2 is a thromboxane A2 metabolite that can help quantify the effects of resistance to aspirin in individuals after ingestion. The primary efficacy outcome was new stroke, the secondary efficacy outcome was a poor functional prognosis (a modified Rankin scale score ≥3), and the primary safety outcome was bleeding, all within the 90-day follow-up period.

Results: A total of 2815 patients were screened and 2663 patients were enrolled in the trial, with 1344 subjects assigned to the intervention group and 1319 subjects assigned to the control group. A total of 60.1% were carriers of the CYP2C19 loss-of-function allele (*2, *3) and 8.71% tested positive for urinary 11-dhTxB2- indicating aspirin resistance in the intervention group. The primary outcome was not different between the intervention and control groups (P = .842). A total of 200 patients (14.88%) in the intervention group and 240 patients (18.20%) in the control group had a poor functional prognosis (hazard ratio 0.77, 95% confidence interval [CI] 0.63 to 0.95, P = .012). Bleeding events occurred in 49 patients (3.65%) in the intervention group and 72 patients (5.46%) in the control group (hazard ratio 0.66, 95% CI 0.45 to 0.95, P = .025).

Conclusions: Personalized antiplatelet therapy based on the CYP2C19 genotype and 11-dhTxB2 levels was associated with favourable neurological function and reduced bleeding risk in acute ischaemic stroke and transient ischaemic attack patients. The results may help support the role of CYP2C19 genotyping and urinary 11-dhTxB2 testing in the provision of precise clinical treatment.

Keywords: 11-dhTxB2; CYP450 2C19 loss-of-function polymorphisms; efficacy and safety; ischaemic stroke; randomized controlled trial.

Abstract

Grants and funding